Syncona Limited Update on Nightstar proposed NASDAQ IPO
September 15 2017 - 7:03AM
UK Regulatory
TIDMSYNC
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSE OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) NO.596/2014
Syncona Limited
Update on Nightstar proposed NASDAQ IPO
15 September 2017
Syncona Ltd ("Syncona"), a leading healthcare company focused on investing in
and building global leaders in life science, today notes that its portfolio
company NightstaRx Limited (which has been reorganised as Nightstar
Therapeutics plc) ("Nightstar") has filed an amended Form F-1 with the U.S.
Securities and Exchange Commission in respect of its proposed initial public
offering ("IPO") in the United States of its American Depositary Shares
("ADSs") representing ordinary shares (available on the SEC's EDGAR database).
The amended Form F-1 filing states an expected pricing range for the proposed
IPO of US$13.00 - $15.00 per ADS, with each ADS representing one ordinary
share. This would represent an increase in value of Syncona's current
shareholding in Nightstar (compared to the 31 July 2017 sterling holding value)
of GBP41.5 - GBP58.3 million[1] (6.3p-8.8p1 per Syncona share).
Syncona has indicated an interest in purchasing ADSs in the IPO, subject to
agreement with the underwriters. The proposed maximum aggregate offering amount
specified in the filing is US$92.46 million, which assumes that the public
offering price is at the top of the range and includes the 15% option to that
is proposed to be granted to the underwriters to cover over-allotments..
A further announcement will be made in due course.
This press release does not constitute an offer to sell or the solicitation of
an offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.
The securities referred to in this release are to be offered only by means of a
prospectus. When available, copies of the preliminary prospectus can be
obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
547-6340, or by email at Prospectus_Department@Jefferies.com; Leerink Partners
LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston,
MA 02110, or by telephone at (800) 808-7525 ext. 6132, or by email at
Syndicate@Leerink.com; or BMO Capital Markets Corp., Attention: Equity
Syndicate Department, 3 Times Square, New York, NY 10036, or by telephone at
(800) 414-3627, or by email at bmoprospectus@bmo.com.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031
Tulchan Communications
Martin Robinson
Tel: +44 (0) 207 353 4200
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of healthcare
while generating superior returns for shareholders. Our current investment
portfolio consists of seven high quality companies in life science and a
leading range of fund investments. We seek to partner with the best, brightest
and most ambitious minds in science to build globally competitive businesses.
We are established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients in areas of
high unmet need.
Our market leading funds portfolio seeks to generate superior returns by
investing in long only and alternative investment funds. This represents a
productively deployed evergreen funding base which enables us to take a long
term approach to investing in life sciences as we target the best new
opportunities and support our existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in UK science,
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both
of which are significant shareholders in our business. We make a donation of
0.3% of Net Asset Value to a range of charities each year.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company focused on
developing and commercializing novel one-time treatments for patients suffering
from rare inherited retinal diseases that would otherwise progress to
blindness.
[1] As at 14 September 2017 foreign exchange rates
END
(END) Dow Jones Newswires
September 15, 2017 08:03 ET (12:03 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2024 to May 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From May 2023 to May 2024